Roughly 70-80% of the 5,000-10,000 US Pompe patients have late-onset disease, yet years often pass before a blood-spot test confirms it.

Pompe disease is an autosomal-recessive metabolic myopathy caused by deficiency of the enzyme acid alpha-glucosidase, leading to glycogen buildup in skeletal, respiratory and, in infants, cardiac muscle. The US Pompe population is estimated at 5,000 to 10,000 patients. Late-onset disease, defined by residual enzyme activity above roughly 1%, accounts for an estimated 70% to 80% of patients and spans a wide phenotype, from near-asymptomatic to wheelchair- and ventilator-dependent. Infantile-onset Pompe, with near-absent enzyme activity, presents within the first months of life with hypertrophic cardiomyopathy and profound low muscle tone, and was historically fatal within the first year without treatment.

Two features define the late-onset landscape. First, diagnosis is slow: patients are frequently worked up for limb-girdle muscular dystrophy or an unexplained myopathy for years before a dried-blood-spot enzyme assay confirms Pompe. Second, respiratory decline, not limb weakness, is the clinical clock; severity tracks disease duration, so earlier-onset patients reach wheelchair and ventilator dependence sooner. Newborn screening is now expanding the pre-symptomatic identified pool and reshaping when and where enzyme replacement therapy begins.

Diagnostic delay, not treatment scarcity, is what defines late-onset Pompe's commercial gap.

Five questions this report answers:

Q1 - What is the size and phenotype split of the US late-onset Pompe population?

Q2 - Where does the diagnostic delay in late-onset Pompe disease come from?

Q3 - Why does respiratory decline, not motor weakness, drive Pompe treatment timing?

Q4 - How does late-onset Pompe differ from infantile-onset Pompe disease?

Q5 - Why is late-onset Pompe disease so often diagnosed late?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #GAA #RareDisease #NewbornScreening #Neuromuscular #USHealthcare

Live report page:  https://axlrx.ai/pompe-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/